Bone Marrow Transplantation (2007) 39, 595–603
& 2007 Nature Publishing Group All rights reserved 0268-3369/07 $30.00
www.nature.com/bmt
ORIGINAL ARTICLE
Experience of severe fatigue in long-term survivors of stem cell
transplantation
MFM Gielissen1, AVM Schattenberg2, CAHHVM Verhagen3, MJ Rinkes2, MEJ Bremmers2 and
G Bleijenberg1
1
Expert Centre Chronic Fatigue, University Medical Centre Nijmegen, Nijmegen, the Netherlands; 2Department of Haematology,
University Medical Centre Nijmegen, Nijmegen, The Netherlands and 3Department of Medical Oncology, University Medical Centre
Nijmegen, Nijmegen, The Netherlands
The literature suggests that cancer survivors with more
aggressive treatments are more at risk for postcancer
fatigue. In this study, we investigated the prevalence of
fatigue after completion of stem cell transplantation
(SCT). Furthermore, we studied if medical variables are
associated with fatigue and if the model of perpetuating
factors of postcancer fatigue derived from previous studies
in cancer survivors, without SCT, is applicable in SCT
survivors. Ninety-eight patients treated with autologous or
allogeneic SCT filled out several questionnaires. Medical
characteristics were obtained from the medical charts. All
patients had to be in persistent complete remission for
at least 1 year. Thirty-five per cent of the patients
experienced severe fatigue. The percentage of patients
with severe fatigue remained stable during the years after
transplantation. Several psychosocial factors, but no
medical factors, were associated with fatigue. The model
of perpetuating factors appeared to be applicable.
Contrary to cancer survivors without SCT, we found no
decrease in fatigue complaints during the first years after
SCT. Cognitive behaviour therapy (CBT) is a general
form of psychotherapy directed at changing conditionrelated cognitions and behaviours. CBT especially designed for postcancer fatigue, aimed at perpetuating
factors, can also be used to manage fatigue in cancer
survivors treated with SCT.
Bone Marrow Transplantation (2007) 39, 595–603.
doi:10.1038/sj.bmt.1705624; published online 19 March 2007
Keywords: cancer survivors; fatigue; stem cell transplantation
Correspondence: Dr MFM Gielissen, Expert Centre Chronic Fatigue
(4628), Radboud University Nijmegen Medical Centre, PO Box 9101,
6500 HB Nijmegen, Gelderland 6525 EC, The Netherlands.
E-mail: M.Gielissen@nkcv.umcn.nl
Received 8 November 2006; revised 23 January 2007; accepted 1
February 2007; published online 19 March 2007
Introduction
Stem cell transplantation (SCT) is a potentially curative
treatment for various malignant diseases. Results are
improving with the course of time and this has led to
reduced morbidity and an increased life expectancy.
Therefore, the number of patients surviving an SCT is
growing during the last decennia. Because SCT is a highly
aggressive and demanding medical intervention, significant
concerns related to the long-term well-being of SCT
survivors have been voiced. Generally speaking, most
patients seemed to have reached an acceptable level of
functioning during the first year after transplant.1–5
However, there seems to be a subgroup of patients who
experience ongoing problems following transplantation.6
One of these problems is persistent fatigue.3,4,7–9
More research has been done in the field of postcancer
fatigue in cancer survivors who were not treated with a
SCT. Fatigue seems to be a problem for about a quarter of
these patients long after curative treatment for cancer, with
profound effects on quality of life.10,11 Furthermore, it
seems that patients with more aggressive treatments are
more at risk for persistent fatigue.12–14 However, little is
known about the aetiology of persistent fatigue and at this
moment, persistent fatigue is unexplainable by somatic
factors. Fatigue seems to be elicited during the treatment
phase, but later on there is no clear relationship between
persistent fatigue and initial disease and cancer treatment
variables.10,11,15–17 Therefore, we think it is useful to make a
distinction between precipitating factors and perpetuating
factors of fatigue after cancer. The assumption is that
cancer itself and/or cancer treatment may have triggered
fatigue (precipitating factors), but other factors are
responsible for the persistence of fatigue complaints
(perpetuating factors).13,18,19
In a previous study, we found cognitive behaviour
therapy (CBT) especially designed for fatigued cancer
survivors effective in reducing fatigue and impairment.18
The rationale of this intervention was based on the model
of precipitating and perpetuating factors. The intervention
was focused on six perpetuating factors of postcancer
fatigue: (1) insufficient coping with the experience of
cancer, (2) fear of disease recurrence,13,16 (3) dysfunctional
Severe fatigue after SCT
MFM Gielissen et al
596
cognitions concerning fatigue,19,20 (4) dysregulation of
sleep,10,11 (5) dysregulation of activity and10,11,16 (6) low
social support and negative social interactions.19
However, in this last study, none of the patients included
were treated with a SCT. Therefore we conducted this
study, to answer the following research questions:
1. What is the prevalence of severe fatigue in patients after
successful SCT?
2. Is the model of precipitating and perpetuating factors
found in other cancer survivors also applicable in cancer
survivors treated with a SCT?
(a) Is there a relationship between past and/or current
medical characteristics and fatigue severity?
(b) Are the same perpetuating factors, that play a role
in persistent fatigue after curation for solid tumours,
involved in fatigue after successful SCT?
Methods
Patients
This study involved all patients who were treated at the age
of 18 or older with an autologous or an allogeneic SCT
between 1981 and 2003 at the Department of Haematology
of the Radboud University Nijmegen Medical Centre.
Diagnoses included were acute myeloid or lymphatic
leukaemia in first complete remission (CR1), chronic
myeloid leukaemia in first chronic phase (CP1), nonHodgkin’s lymphoma in CR1. The conditioning regime
included total body irradiation. All patients had to be in
persistent complete remission for at least 1 year after SCT.
Graft-versus-host disease (GVHD) is a frequent complication of an allogeneic SCT in which the engrafted donor
cells attack the patient’s organs and tissue. Acute GVHD
was classified as grades I–IV according to Glucksberg
et al.21 and chronic GVHD as limited or extensive following
the Shulman criteria.22 Patients with severe GVHD after
allogeneic SCT (i.e. grades III and IV, acute GVHD or
extensive chronic GVHD) may experience many acute and
chronic medical problems, are treated with several drugs
and other therapies, which may influence an unstable
clinical balance and may provoke fatigue. Therefore, these
patients were excluded from this study.
Anaemia is a well-known physical factor that can cause
fatigue. Therefore, all patients with a haemoglobin (Hb)
concentration of 10 g/dl and lower were not eligible for this
study.
Recruitment procedure
All patients that underwent SCT since 1981 could be
identified by a database that was set up at the research
centre of the Department of Haematology. Inclusion and
exclusion criteria were checked according to the data of the
most recent clinical check-up. All patients were sent a
package of questionnaires and an informed consent form,
together with a letter of their physician, explaining the
purpose of the study. Patients were asked to fill out and
Bone Marrow Transplantation
send back the questionnaires together with the informed
consent to the Expert Centre Chronic Fatigue. The Ethics
Committee of the hospital approved the study.
Demographic and medical characteristics
The demographic characteristics like age, gender, marital
status, education and employment were gathered by selfreport.
Characteristics of the medical history of patients were
obtained from the medical chart and consisted of type of
diagnosis, type of transplantation, time since transplantation, grade of GVHD, duration of hospitalization during
SCT and number of hospitalizations for complications
after SCT. Additionally, we acquired information about
current medical characteristics from the medical chart, like
comorbidity, medication use, Hb concentration and body
mass index (BMI) at time of participation in the study.
Questionnaires
Fatigue severity was measured by the ‘fatigue severity’
subscale (CIS-fatigue) of the Checklist Individual Strength
(CIS),23–26 consisting of eight items designed to measure
fatigue severity during the previous 2 weeks. Each item was
scored on a 7-point Likert scale. High scores indicated a
high level of fatigue. A CIS-fatigue score equal or higher
than 35 was used to identify severe fatigue.19,23 The
questionnaire has been used in cancer survivors,13,18,19,27,28
showed good reliability, discriminative validity and sensitivity to change.18,22,29,30
Coping with the experience of fatigue was measured with
the Dutch version of the Impact of Event Scale. This 15item scale consists of two subscales (intrusion: seven items
and avoidance: eight items) on a 6-point Likert scale and
measures the extent to which a subject is currently occupied
with the coping process after a major event (in this study,
the diagnose and treatment for cancer). High scores are
indicative for intrusively experienced ideas, images, feelings
or bad dreams about the event and avoidance of unpleasant
feelings or memories of the event.31–33
Fear of disease recurrence was measured by two items of
the Cancer Acceptance Scale (CAS) scored on a 4-point
Likert scale.13 The items are (1) I am worried about a
tumour relapse, (2) I am anxious about my health. High
scores are indicative of a high level of fear.
Cognitions related to fatigue. Self-efficacy was measured
with the Self-Efficacy Scale (SES), consisting of five
questions, which measured sense of control in relation to
fatigue complaints.13,19,30,34 Cancer-related attributions
with regard to fatigue complaints were measured with the
Causal Attribution List (CAL),19 consisting of four items
(cancer, SCT, radiation therapy, chemotherapy). For
each item, patients were asked to indicate their opinion
regarding the cause of their fatigue complaints on a 4-point
scale (1 ¼ not at all applicable to 4 ¼ very applicable).
Internal reliability of this questionnaire was good, with a
Cronbach’s a coefficient 0.95.
Sleep disturbances was measured with the sleep/rest
subscale of the Sickness Impact Profile (SIP-8),35,36 and
the insomnia subscale of the Quality of Life Questionnaire-
Severe fatigue after SCT
MFM Gielissen et al
597
C30 (QLQ-C30),37 with higher values reflecting an increased presence of symptoms.
Physical activity was measured with the physical
functioning and role functioning subscale of the QLQC30, with higher scores representing a better level of
physical/role functioning. Furthermore, physical activity
was measured with the subscales: home management, work,
and recreation and pastimes from the SIP, with high scores
reflecting more functional impairments.
Social functioning was measured with the social functioning subscale of the QLQ-C30 and the social interaction
subscale of the SIP.
Statistical analysis
Data analyses were performed using Statistical Package for
Social Science (SPSS; version 12.1). Descriptive statistics
were used for description of the sample. w2, independent
samples t-tests and analyses of variance general linear
model (GLM) have been performed to test differences
between groups. Pearson correlations were used to investigate the association between fatigue severity (CISfatigue) and medical characteristics. Furthermore, Pearson
correlations between fatigue severity and the six perpetuating factors were used as preparatory analyses to examine
the contribution of these factors to fatigue severity. Those
measures that correlated highest with the fatigue severity
score were used as independent variables in a linear
regression analyses (enter-method). Correlations between
the six perpetuating factors were tested on multicolinearity
(ro0.9).
Table 1
Demographic and medical characteristics (n ¼ 98)
Cancer survivors treated with
a SCT (n ¼ 98)
Age
45.3 (10.9) range ¼ 19.0–67.3
Gender
Male
Female
57 (58%)
41 (42%)
Marital status
Married/cohabiting
Unmarried
Divorced
Widowed
77
17
2
2
Higher education (X12 years)
34 (35%)
Employment
Work outside home
Study
Disablement insurance act
Partial disablement insurance act
Sick leave
No work
54
6
26
7
3
4
Primary diagnosis
Acute leukaemia
Chronic leukaemia
Lymphoma
70 (72%)
21 (21%)
7 (7%)
Transplantation
Allogeneic
Autologous
79 (81%)
19 (19%)
Time since transplantation (years)
(79%)
(17%)
(2%)
(2%)
(54%)
(6%)
(26%)
(7%)
(%)
(4%)
9.3 (5.5) range ¼ 1.0–21.5
Abbreviation: SCT ¼ stem cell transplantation.
Results
Response
Hundred twenty-four patients met the eligibility criteria
and were asked to participate in this study. Ultimately, the
questionnaires were filled out and returned by 98 patients
(79%). Reasons for non-participation (n ¼ 26) were: too
emotional to participate (n ¼ 6), did not feel like taking part
because they had no complaints at the moment (n ¼ 3), bad
concentration and therefore not able to fill out the
questionnaires (n ¼ 1) and unknown (n ¼ 16). Non-participants did not differ from the participants with regard to
demographic characteristics (data not shown), except for
age. Nonparticipants were significantly younger compared
with the participants (40.5 (s.d. ¼ 8.9) vs 45.3 (s.d. ¼ 10.8);
P ¼ 0.038). Information about demographic, disease and
treatment characteristics of the participants are listed in
Table 1.
Research questions
What is the prevalence of severe fatigue in patients after
successful SCT? The mean CIS-fatigue severity score of
the total sample was 26.9 (s.d. ¼ 14.0). Thirty-four patients
(35%) meet the cutoff criteria for severe fatigue (CISfatigueX35), whereas an additional 12 patients (12%) had
heightened fatigue scores (CIS-fatigue between 27 and 35).
There were no differences in fatigue severity between
male (27.6, s.d. ¼ 14.0) and female cancer survivors (25.9,
s.d. ¼ 14.2, P-value ¼ 0.558), younger (24.7, s.d. ¼ 12.6)
and older survivors (29.0, s.d. ¼ 15.1, P-value ¼ 0.125)
(median ¼ 45.7 years), married/cohabiting (27.0, s.d. ¼
14.0) and unmarried/divorced/widowed survivors (26.5,
s.d. ¼ 14.3, P ¼ 0.880) and survivors with lower and
higher education, respectively 27.7 (s.d. ¼ 14.9) and 26.0
(s.d. ¼ 12.2) (P ¼ 0.552).
Is there a relationship between past and/or current medical
characteristics and fatigue severity?
Medical history. Diagnose and transplantation: No
significant difference was seen in mean fatigue score
between patients who were diagnosed with acute leukaemia, chronic leukaemia or lymphoma and between patients
who were treated with allogeneic transplantation or
autologous transplantation (Table 2).
Time since transplantation: To investigate the relationship between fatigue severity and time since transplantation, the total sample has been divided into four groups:
patients who were treated with a SCT between 1 and 5
years ago (n ¼ 32), between 5 and 10 years ago (n ¼ 19),
between 10 and 15 years ago (n ¼ 30) and more than 15
years ago (n ¼ 17). Mean fatigue scores and percentages of
severe fatigue for these four groups are shown in Table 3.
No statistically significant differences were found in mean
fatigue scores and in percentages of severe fatigue. In
Bone Marrow Transplantation
Severe fatigue after SCT
MFM Gielissen et al
598
Table 2
The association of fatigue with medical characteristics (medical charts)
n
Mean CIS-fatigue (s.d.)
P-value
Diagnosis
Acute leukaemia
Chronic leukaemia
Lymphoma
70
21
7
27.3 (13.9)
27.8 (14.2)
22.9 (16.0)
0.733
Transplantation
Allogeneic
Autologous
79
19
27.6 (13.9)
23.8 (14.4)
0.285
Graft-versus-host disease
Absent
Grade I
Grade II
36
34
9
26.8 (13.8)
29.4 (14.5)
24.4 (12.4)
0.562
Duration of hospitalization SCT
p5 weeks
45 weeks
51
47
27.3 (13.4)
26.5 (14.8)
0.471
Hospitalizations after SCT for complications
0 hospitalizations
1 hospitalization
41 hospitalization (range ¼ 2–7)
55
26
17
24.7 (12.5)
28.9 (15.9)
31.1 (15.2)
0.181
Comorbidity at the time of participation
(7 missing)
Yes
No
38
53
31.7 (14.9)
24.7 (12.7)
0.018
Medication at the time of participation
No medication
Medication but no antibiotics
And/or beta blocker
Antibiotics
Beta blocker
51
25.8 (13.5)
17
11
9
29.9 (14.8)
35.8 (14.9)
26.6 (13.7)
0.174
Hb concentration at the time of participation
¼ Normal concentration
oNormal concentration
78
20
26.7 (14.1)
27.6 (14.0)
0.814
BMI at the time of participation
Normal BMI
4Or onormal BMI
53
45
25.0 (12.6)
29.1 (15.4)
0.156
Abbreviations: BMI ¼ body mass index; CIS ¼ Checklist Individual Strength; SCT ¼ stem cell transplantation.
Table 3
Mean CIS-fatigue scores and percentages of fatigue for patients who finished SCT within a different time period
n
Time since transplantation
Between 1 and 5 years ago
Between 5 and 10 years ago
Between 10 and 15 years ago
More than 15 years ago
32
19
30
17
Total
98
Mean CIS-fatigue (s.d.)*
27.5
28.4
25.4
26.7
(12.3)
(14.2)
(14.5)
(16.9)
% of severe fatigue**
41
32
30
35
Abbreviations: CIS ¼ Checklist Individual Strength; GLM ¼ general linear model; SCT ¼ stem cell transplantation.
*Analyses of variance (GLM), P ¼ 0.901.
**w2, P ¼ 0.832.
addition, the correlation between the CIS-fatigue score and
time since transplantation proved to be very low and
nonsignificant (Figure 1).
GVHD: From the medical charts, we obtained for each
patient the maximum GVHD grade after transplantation.
Bone Marrow Transplantation
As described in the Methods section, patients with severe
GVHD were excluded. There were no differences in the
mean fatigue score between patients who experienced
no GVHD after transplantation, or who suffered from
grade I or II.
Severe fatigue after SCT
MFM Gielissen et al
599
(c) remaining comorbidities (n ¼ 15, five diabetes mellitus,
six hypercholesterolaemia, two epilepsy, one haematuria, one gout).
Within these three groups, mean fatigue scores were,
respectively, 33.9 (s.d. ¼ 14.7), 33.2 (s.d. ¼ 15.0) and 28.9
(s.d. ¼ 15.5) and were not significantly different (P ¼ 0.662).
Medication use: We investigated medication use by
patients at the moment of participation in the study. There
was no significant difference between postcancer fatigue in
patients
60
50
CIS-fatigue
40
30
(a)
(b)
(c)
(d)
20
10
0
0.00
5.00
10.00
15.00
20.00
Time since transplantation (years)
25.00
Figure 1 The association of time since treatment with fatigue severity
(CIS-fatigue); r ¼ 0.080, P ¼ 0.434.
Hospitalization and complications: To analyse the association between postcancer fatigue and the duration of
hospitalization during the transplantation, the group was
divided into two groups based on the median time of
hospitalization (5 weeks). No difference in mean fatigue
scores of the two groups was found. Furthermore, the
correlation between the fatigue score and total days of
hospitalization was nonsignificant (r ¼ 0.046, P ¼ 0.652).
Owing to complications, 44% of the patients (n ¼ 43) had
been re-admitted after the SCT (n ¼ 5, abdominal pain;
n ¼ 9, nausea/vomiting/diarrhoea; n ¼ 21, fever; n ¼ 9,
respiratory insufficiency/failure; n ¼ 7, Herpes Zoster;
n ¼ 11, other complications). No difference was found
between the mean fatigue score of patients who had no
complications after transplantation, patient who had been
hospitalized once, and patients who had been hospitalized
more than one time. Additionally, post-treatment fatigue
was not related to the number of hospitalizations and to the
number of days of hospitalization due to complications
(respectively, r ¼ 0.128, P ¼ 0.208; r ¼ 0.043 P ¼ 0.676).
Current medical characteristics. Comorbidity: Patients
with comorbidity at the time of participation (n ¼ 38) were
significantly more fatigued than patients without comorbidity (n ¼ 53; P ¼ 0.018) (Table 2). The group of patients
with comorbidity was divided into three subgroups;
(a) comorbidity that possibly can cause fatigue (n ¼ 10;
four hepatitis C, four hypertension with use of a beta
blocker, two recurrent respiratory infections);
(b) co-morbidity possibly caused by the SCT (n ¼ 13, six
iron overload, five good controlled hypothyroidism
(normal levels of thyroid stimulating hormone (TSH)
and Free T4 at the time of participation in the study),
two postherpetic neuralgia);
without medication (n ¼ 51),
with antibiotics (n ¼ 11),
with beta blocker (n ¼ 9),
with other medication (n ¼ 17).
Hb concentration: To test the association between
postcancer fatigue and the Hb concentration at the moment
of participation, two subgroups were identified based on
the normal distribution of Hb concentration of the
WHO.38,39 No difference was seen in the mean fatigue
score between patients with a normal Hb concentration
(n ¼ 78: men ¼ 13.6–17.2 g/dl; women ¼ 12–15 g/dl) and
patients with a low Hb concentration (n ¼ 20: men ¼
13.6 g/dl; women ¼ o12 g/dl). Additionally, the correlation
between fatigue severity and Hb concentration was nonsignificant (r ¼ 0.024, P ¼ 0.813).
BMI: Based on WHO standards, BMI was categorized as
underweight (BMIo18.5), normal weight (BMI ¼ 18.5–
24.9), overweight (BMI ¼ 25–29.9) and obese (BMIX30).40
To analyse the association between postcancer fatigue and
the weight of patients at the time of participation, the total
group was divided into two groups. Patients with a normal
weight (n ¼ 53) and patients with underweight, overweight
and obese patients (n ¼ 43). There was no difference in
fatigue severity between these two groups. Additionally, the
correlation between fatigue severity and BMI was low and
nonsignificant (r ¼ 0.098, P ¼ 0.338).
Are the same perpetuating factors, that play a role in
persistent fatigue after curation for solid tumours, involved
in fatigue after successful SCT? In Table 4, comparisons
have been made between fatigued cancer survivors
(CISX35) and non-fatigued cancer survivors (CISo35)
with regard to the six perpetuating factors. Results were
consistent; patients experiencing severe fatigue had more
difficulties in coping with the experience of cancer, more
fear of disease recurrence, more dysfunctional cognitions,
sleep disturbances, less physical activity and low social
functioning. Furthermore, all measurements correlated
significantly with the fatigue severity score.
The highest correlations were used as independent
variables in a linear regression analyses. There was no
multicolinearity between the six perpetuating factors
entered in the regression analyses. Results of the regression
analyses (Table 5) indicated that insufficient coping with
the experience of fatigue, fear of disease recurrence, low
self-efficacy, sleep disturbances and low role functioning
contributed significantly to fatigue severity. In total, 68%
of the variance of fatigue severity was explained by the six
perpetuating factors.
Bone Marrow Transplantation
Severe fatigue after SCT
MFM Gielissen et al
600
Table 4
Comparisons between severely fatigued cancer survivors (CIS X35) and nonfatigued cancer survivors (CIS o35) long after SCT
Coping with the experience of fatigue
Impact of event scale
Nonfatigued (n ¼ 64)
Severe fatigued (n ¼ 34)
P-value
7.6 (10.6)
16.5 (16.1)
0.004
0.380**
Correlation: CIS-fatigue
Fear of disease recurrence
Cancer acceptance scale
12.7 (3.3)
16.8 (4.9)
0
0.454**
Dysfunctional cognitions
Self-efficacy (SES)
Cancer-related attributions (CAL)
22.3 (3.6)
11.1 (4.0)
17.4 (3.3)
14.7 (1.9)
0
0
0.639**
0.599**
Sleep disturbances
Sleep/rest (SIP)
Insomnia (QLQ-C30)
20.5 (36.9)
13.0 (21.1)
85.1 (76.4)
29.4 (35.5)
0
0.021
0.550**
0.407**
Dysregulation of physical activity
Home management (SIP)
Recreation and pastimes (SIP)
Work (SIP)
Physical functioning (QLQ-C30)
Role functioning (QLQ-C30)
32.0
30.1
61.7
91.8
94.5
0
0
0.001
0
0
0.514**
0.518**
0.358**
0.614**
0.675**
Social functioning
Social functioning (QLQ-C30)
Social interactions (SIP)
90.4 (18.3)
52.1 (92.7)
0
0
0.472**
0.544**
(66.9)
(53.6)
(125.0)
(13.7)
(11.2)
93.3
91.7
149.5
71.8
57.8
(70.6)
(71.7)
(157.0)
(13.7)
(30.5)
71.1 (25.4)
150.3 (136.1)
Abbreviations: CAL ¼ Causal Attribution List; CIS ¼ Checklist Individual Strength; QLQ-C30 ¼ Quality of Life Questionnaire-C30; SES ¼ Self-Efficacy
Scale; SIP ¼ Sickness Impact Profile.
**Po0.01.
Table 5
Linear regression (enter) to predict fatigue severity
Independent variables
Coping with the experience of cancer (IES)
Fear of disease recurrence (CAS)
Dysfunctional cognitions (SES)
Sleep disturbances (SIP-sleep/rest)
Dysregulation of physical activity (QLQ-C30 – role functioning)
Social functioning (SIP – social interactions)
Total R2 (adjusted)
Dependent variable: CIS-fatigue severity
Beta
P-value
0.172
0.175
0.243
0.215
0.376
0.005
0.016
0.034
0.002
0.007
0.000
0.958
0.679
Abbreviations: CIS ¼ Causal Attribution List; CAS ¼ Cancer Acceptance Scale; IES ¼ Impact of Event Scale; QLQ-C30 ¼ Quality of Life QuestionnaireC30; SES ¼ Self-Efficacy Scale; SIP ¼ Sickness Impact Profile.
Discussion
In this study, 35% of a group of patients experienced severe
fatigue long after finishing SCT (mean ¼ 9.3 years). The
percentage cancer survivors with severe fatigue remained
stable during the years after transplantation, even after
more than 15 years.
Cross-sectional studies investigating the prevalence of
fatigue (all not including patients who were treated with a
SCT) showed that the percentage of cancer survivors with
severe fatigue decreases during the years after treatment:
this was 38% after 2.5 years,19 30% after 3 year,41 37%
after 4 years,42 26% after 12 years43 and 16% after 12
years.44 The course of fatigue was also investigated in four
longitudinal studies, measuring the prevalence of fatigue in
cancer survivors two times at different time points. Bower
et al.12 found a decrease of 35% (3.5 years after treatment)
Bone Marrow Transplantation
to 21% (6.3 years after treatment) and Servaes et al.27
found a decrease of 38% (2.5 years after treatment) to 23%
(4.5 years after treatment). In the two other longitudinal
studies, the percentage of patients with severe fatigue
remained equal, 28% (6 after treatment) to 26% (8 years
after treatment)12 and Hjermstad et al.15 investigated
disease-free cancer patients 16 and 24 years after treatment
for cancer. In this longitudinal study, the percentage of
fatigued cancer survivors was respectively, 25% and 28%.
These results seem to suggest that fatigue complaints
continue to decrease during the first 3–4 years after curative
treatment and remains a persistent problem for about a
quarter of the cancer survivors. However, in the current
study we investigated the course of fatigue, and we found
no decrease of fatigue even up to 15 years after completing
SCT. So it seems that in patients after a SCT the percentage
of fatigue remains high. This finding is in agreement with
Severe fatigue after SCT
MFM Gielissen et al
601
the assumption that patients with more aggressive treatments are more at risk for persistent fatigue.12–14,45
The respondent sample consist of almost 80% of the
patients who were treated for acute leukaemia in CR1,
non-Hodgkin lymphoma in CR1 and chronic leukaemia’s
in CP1. The population of (A)SCT patients from the
Department of Hematology of the Radboud University
Nijmegen Medical Centre does not differ from other Dutch
and European centres for (A)SCT.46 Our study involved
patients who were 18 years or older at the time of (A)SCT
and who had to be in persistent CR for at least 1 year after
(A)SCT. Patients with acute GVHD grade III or IV and/or
extensive GVHD were excluded and this was also true for
patients with a Hb concentration of 10 g/dl at the time of
inclusion. This is given in the Methods section. The
exclusion of patients with severe acute or severe chronic
GVHD and the exclusion of patients with a Hb level of less
than 6.0 g/dl may result in a respondent sample with
relatively more patients who are less prone to fatigue than
the general population after (A)SCT. This means that the
impressive number of patients that experienced severe
fatigue will be even higher in a general (A)SCT population.
We found no associations with fatigue severity and
characteristics of the medical history. Owing to shorter time
in protective isolation, fewer treatment-related side effects
and no risk of GVHD, the assumption has been uttered
that patients with allogeneic SCT have more late effects
than patients with a autologous SCT. However, the
literature is ambiguous on this point.1,47–50 Concerning
fatigue, Hjermstad et al.1 also found no differences between
the two types of transplantation. However, similar to their
studies, the small number of patients in our autologous
group implies that chance findings cannot be ruled out.
Because in this study the focus was on fatigue with no
somatic cause, we excluded beforehand patients with
medical problems that could possibly cause fatigue, like
GVHD grade of III and IV and Hb concentration of 10 g/dl
and lower. This could be the reason why no relation
between fatigue severity and somatic characteristics were
found.
Thirty-eight of the 98 patients (39%) had a medical
comorbidity besides persistent fatigue. Patients with a
medical comorbidity scored higher on fatigue severity
compared with patients without a medical comorbidity.
However, no differences were found in fatigue severity
between the different kinds of medical comorbidity
(comorbidity that possibly can cause fatigue, comorbidity
possibly caused by the SCT and the remaining comorbidities). Because of the relatively small numbers of patients in
the different groups, an actual difference cannot be ruled
out fully.
The model of perpetuating factors derived from previous
studies in cancer survivors, not undergoing transplantation,
appears to be applicable in SCT cancer survivors as well.
Persistent fatigue was well predicted by the supposed
perpetuating factors: insufficient coping with the experience
of cancer, fear of disease recurrence, dysfunctional cognitions concerning fatigue, dysregulation of sleep and
dysregulation of activity. In total, 68% of the variance of
fatigue severity was explained by the six factors. Only
impairment in social functioning did not contribute
significantly to fatigue severity. Servaes et al.19 demonstrated that severely fatigued cancer survivors experienced
more negative interactions and insufficiency of supporting
interactions than those who were not fatigued. No
significant difference was found in the frequency of
supporting interactions. So, it seems that the experienced
insufficiency and negative interactions have more influence
on fatigue severity than impairment in social functioning as
measured in this study. Additionally, these results suggest
that in the absence of clear medical causes, the CBT
especially designed for fatigued cancer survivors after
conservative treatment, can also be used in the management of fatigue after SCT.
The strength of this paper is characterized by an
underlying theoretical perspective of postcancer fatigue,
the model of precipitating and perpetuating factors.
However, it could be argued that the factors do not
perpetuate fatigue, but represent, for example, psychosocial
consequences of stress. Furthermore, the study is crosssectional and limits our ability to draw conclusions about
the course of postcancer fatigue in patients following a
SCT. For definitive conclusions, a longitudinal design
would be more appropriate.
Acknowledgements
We thank all the patients who gave their time to participate in
the study. Carmen Ariens and Tiny Fasotti for assisting in data
collection. Funding for this study was provided by the Interzol,
Comprehensive Cancer Centre South.
References
1 Hjermstad MJ, Evensen SA, Kvaloy SO, Fayers PM, Kaasa S.
Health-related quality of life 1 year after allogeneic or
autologous stem-cell transplantation: a prospective study.
J Clin Oncol 1999; 17: 706–718.
2 Hjermstad MJ, Holte H, Evensen SA, Fayers PM, Kaasa S.
Do patients who are treated with stem cell transplantation
have a health-related quality of life comparable to the general
population after 1 year? Bone Marrow Transplant 1999; 24:
911–918.
3 Hjermstad MJ, Knobel H, Brinch L, Fayers PM, Loge JH,
Holte H et al. A prospective study on health-related quality of
life, fatigue, anxiety and depression 3–5 years after stem cell
transplantation. Bone Marrow Transplant 2004; 34: 257–266.
4 Lee SJ, Fairclough D, Parsons SK, Soiffer RJ, Fisher DC,
Schlossman RL et al. Recovery after stem-cell transplantation
for hematologic diseases. J Clin Oncol 2001; 19: 242–252.
5 Bush NE, Donaldson GW, Haberman MH, Dacanay R,
Sullivan KM. Conditional and unconditional estimation of
multidimensional quality of life after hematopoietic stem cell
transplantation: a longitudinal follow-up of 415 patients.
Biol Blood Marrow Transplant 2000; 6: 576–591.
6 Neitzert CS, Ritvo P, Dancey J, Weiser K, Murray C, Avery J.
The psychosocial impact of bone marrow transplantation: a
review of the literature. Bone Marrow Transplant 1998; 22:
409–422.
7 Hann D, Jacobsen PB, Martin SC, Kronish LE, Azzarello LM,
Fields KK. Fatigue in women treated with bone marrow
transplantation for breast cancer: a comparison with women
with no history of cancer. Support Care Cancer 1997; 5: 44–52.
Bone Marrow Transplantation
Severe fatigue after SCT
MFM Gielissen et al
602
8 Andrykowski MA, Bishop MM, Hahn EA, Cella DF,
Beaumont JL, Brady MJ et al. Long-term health related
quality of life, growth, and spiritual well-being after hematopoietic stem cell transplantation. J Clin Oncol 2005; 23:
599–608.
9 Knobel H, Loge JH, Nordoy T, Kolstad AL, Espevik T,
Kvaloy S, Kaasa S. High level of fatigue in lymphoma patients
treated with high dose therapy. J Pain Symptom Manage 2000;
19: 446–456.
10 Servaes P, Verhagen C, Bleijenberg G. Fatigue in cancer
patients during and after treatment: prevalence, correlates and
interventions. Eur J Cancer 2002; 38: 27–43.
11 Prue G, Rankin J, Allen J, Gracey J, Cramp F. Cancer related
fatigue: a critical appraisal. Eur J Cancer 2006; 42: 846–863.
12 Bower JE, Ganz PA, Desmond KA, Bernaards C, Rowland
JH, Meyerowitz BE et al. Fatigue in long-term breast
carcinoma survivors. A longitudinal investigation. Cancer
2006; 106: 751–758.
13 Servaes P, Verhagen C, Schreuder BHW, Veth RPH, Bleijenberg G. Fatigue after treatment for malignant and benign bone
and soft tissue tumors. J Pain Symptom Manage 2003; 26:
1113–1122.
14 Woo B, Dibble SL, Piper BF, Keating SB, Weiss MC.
Differences in fatigue by treatment methods in women with
breast cancer. Oncol Nurs Forum 1998; 25: 915–920.
15 Hjermstad SD, Fosså SD, Oldervoll L, Holte H, Jacobsen AB,
Loge JH. Fatigue in long-term Hodgkin’s disease survivors:
a follow-up study. J Clin Oncol 2005; 23: 6587–6595.
16 Young KE, White CA. The prevalence and moderators of
fatigue in people who have been successfully treated for cancer.
J Psychosom Res 2006; 60: 29–38.
17 Ng AK, Li S, Recklitis C, Neuberg D, Chakrabartis S, Silver B
et al. A comparison between long-term survivors of Hodgkin’s
disease and their siblings on fatigue level and factors predicting
for increased fatigue. Ann Oncol 2005; 16: 1949–1955.
18 Gielissen MFM, Verhagen C, Witjes JA, Bleijenberg G. Effects
of cognitive behavior therapy in severely fatigued disease-free
cancer patients compared with patients waiting for cognitive
behavior therapy: a randomized controlled trial. J Clin Oncol
2006; 23: 4882–4887.
19 Servaes P, Verhagen C, Bleijenberg G. Determinants of
chronic fatigue in disease-free breast cancer patients, a crosssectional study. Ann Oncol 2002; 13: 589–598.
20 Broeckel JA, Jacobsen PB, Horton J, Balducci L, Lyman GH.
Characteristics and correlates of fatigue after adjuvant
chemotherapy for breast cancer. J Clin Oncol 1998; 16:
1689–1696.
21 Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE,
Clift RA et al. Clinical manifestations of graft-versus-host
disease in human recipients of marrow from HLA-matched
sibling donors. Transplantation 1974; 18: 295–304.
22 Shulman HM, Sullivan KM, Weiden PL, McDonald GB,
Striker GE, Sale GE et al. Chronic graft-versus-host syndrome
in man. Am J Med 1980; 69: 204–217.
23 Vercoulen JHHM, Swanink CMA, Fennis JFM, Galama
JMD, van der Meer JWM, Bleijenberg G. Dimensional
assessment of chronic fatigue syndrome. J Psychosom Res
1994; 38: 383–392.
24 Beurskens AJHM, Bultman U, Kant IJ, Vercoulen JHMM,
Bleijenberg G, Swaen GMH. Fatigue among working people:
validity of a questionnaire measure. Occup Environ Med 2000;
57: 353–357.
25 Dittner AJ, Wessley SC, Brown RG. The assessment of
fatigue: a practical guide for clinicians and researchers.
J Psychosom Res 2004; 56: 157–170.
26 Reeves WC, Lloyd A, Vernon SD, Klimas N, Jason LA,
Bleijenberg G et al. The Intrenational Chronic Fatigue
Bone Marrow Transplantation
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
Syndrome Study Group. Identification of ambiguities in the
1994 chronic fatigue syndrome research case definition and
recommendations for resolution. BMC Health Serv Res 2003;
3: 25.
Servaes P, Gielissen MFM, Verhagen S, Bleijenberg G. The
course of severe fatigue in disease-free breast cancer patients: a
longitudinal study. Psycho-Oncology (E-pub ahead of print).
Servaes P, Prins J, Verhagen S, Bleijenberg G. Fatigue after
breast cancer and in chronic fatigue syndrome: similarities and
differences. J Psychosom Res 2002; 52: 453–459.
Stulemeijer M, de Jong LWAM, Fiselier TJW, Hoogveld
SWB, Bleijenberg G. Cognitive behaviour therapy for adolescents with chronic fatigue syndrome: randomised controlled
trial. Br Med J 2005; 330: 14.
Prins JB, Bleijenberg G, Bazelmans E, Elving LD, de Boo
ThM, Severens JL et al. Cognitive behaviour therapy for
chronic fatigue syndrome: a multicentre randomised controlled
trial. Lancet 2001; 357: 841–847.
Brom D, Kleber RJ. De Schok Verwerkings Lijst [the impact
of event scale – Dutch adaptation]. Ned Tijdschr Psych 1985;
40: 164–168.
Van der Ploeg E, Mooren TTM, Kleber RJ, van der Velden
PG, Brom D. Construct validation of the Dutch version of the
impact of event scale. Psych Assess 2004; 16: 16–26.
Creamer M, Bell R, Failla S. Psychometric properties of
the impact of event scale – revised. Behav Res Ther 2003; 41:
1489–1496.
Vercoulen JH, Swanink CM, Galama JM, Fennis JFM,
Jongen PJH, Hommes OR et al. The persistence of fatigue in
chronic fatigue syndrome and multiple sclerosis: development
of a model. J Psychosom Res 1998; 45: 507–517.
Bergner M, Bobbitt RA, Carter WB, Gilson BS. The sickness
impact profile. Development and final revision of a health
status measure. Med Care 1981; 19: 787–805.
Jacobs HM, Luttik A, Touw-Otten FW, de Melker RA. The
sickness impact profile; results of an evaluation study of the
Dutch version] De ‘sickness impact profile’; resultaten van een
valideringsonderzoek van de Nederlandse Versie. Ned Tijdschr
Geneeskd 1990; 134: 1950–1954.
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull M,
Duez NJ et al. The European organization for research and
treatment of cancer QLQ-C30: a quality-of-life instrument for
use in international clinical trials in oncology. J Natl Cancer
Inst 1993; 85: 365–376.
World Health Organization. Group of Experts. Nutritional
Anaemias. WHO Technical report series no. 503. WHO:
Geneva, 1972.
Pronk-Admiraal CJ, Van Alphen-Jager JM, Herruer MH.
Regionale uniformering van hematologische referentiewaarden. Ned Tijdschr Klin Chem 1997; 22: 192–194.
Report of a WHO consultation. Obesity: preventing, managing
the global epidemic. 2000; 894: I–XII , 1–253. World Health
Organization. World Health Organ Tech Rep Sez.
Bower JE, Ganz PA, Desmond KA, Rowland JH, Meyerowitz
BE, Belin TR. Fatigue in breast cancer survivors: occurrence,
correlates, and impact on quality of life. J Clin Oncol 2000; 18:
743–753.
Sugawara Y, Akechi T, Okuyama T, Matsuoka Y, Nakano T,
Inagati M et al. Occurrence of fatigue and associated factors in
disease-free cancer patients without depression. Support Care
Cancer 2005; 13: 628–636.
Loge HJ, Abrahamsen AF, Ekeberg O, Kaasa S. Fatigue and
psychiatric morbidity among Hodgkin’s disease survivors.
J Pain Symptom Manage 2000; 19: 91–99.
Fossa SD, Dahl AA, Loge JH. Fatigue, anxiety and depression
in long-term survivors of testicular cancer. J Clin Oncol 2003;
21: 1249–1254.
Severe fatigue after SCT
MFM Gielissen et al
603
45 De Jong N, Candel MJJM, Schouten HC, Huijer Abu-Saad H,
Courtens AM. Prevalence and course of fatigue in breast
cancer patients receiving adjuvant chemotherapy. Ann Oncol
2004; 15: 896–905.
46 Gratwohl A, Baldomero H, Frauendorfer K, Urbano-Ispizua
A, Niederwieser D, For the joint accreditation committee of
the International Society for Cellular Therapy ISCT and the
European Group for Blood and Marrow Transplantation
EBMT (JACIE). Results of the EBMT activity survey 2005 on
haematopoietic stem cell transplantation: focus on increasing
use of unrelated donors. Bone Marrow Transplant 2007; 39:
71–87.
47 Zittoun R, Suciu S, Watson M, Solbu G, Muus P, Mandelli F
et al. Quality of life in patients with acute myelogenous
leukemia in prolonged first complete remission after bone
marrow transplantation (allogeneic or autologous) or chemotherapy: a cross-sectional study of the EORTC-GIMEMA
AML 8a trial. Bone Marrow Transplant 1997; 20: 307–315.
48 Andrykowsky MA, Greiner CB, Altmaier EM, Burish TG,
Antin JH, Gingrich R et al. Quality of life following bone
marrow transplantation: findings from a multicentre study.
Brit J Cancer 1995; 71: 1322–1329.
49 Meyers CA, Wietzner M, Byrne K, Valentine A, Champlin
RE, Przepiorka D. Evaluation of the neurobehavioural
functioning of patients before, during and after bone marrow
transplantation. J Clin Oncol 1994; 12: 820–826.
50 Prieto JM, Saez R, Carreras E, Atala J, Sierra J, Rovira M
et al. Physical and psychosocial functioning of 117 survivors of
bone marrow transplantation. Bone Marrow Transplant 1996;
17: 1133–1142.
Bone Marrow Transplantation